The investigators (physicians and staff) at the participating institutions (!3 recruited patients) on behalf of the AGO Breast Study Group are given in the Appendix.
Introduction
For adjuvant treatment of primary breast cancer (BC), anthracycline and taxane-based chemotherapy regimens are considered standard of care [1] . In addition, dose-dense (dd) [2] [3] [4] , intense dd (idd) regimens [5] or tailored dd regimens [6] have shown superior clinical outcomes when compared with conventionally dosed chemotherapy, however, clinical follow-up has been relatively short in these studies [median 5 (range 3-7) years] and long-term clinical outcome data are missing [2, 4, 5, 6] . Hematological toxicity is more pronounced with dd regimens, but grade 3/4 neutropenia and febrile neutropenia can safely be prevented by primary prophylaxis with granulocyte-colony stimulating factors (G-CSF). Primary prophylaxis even leads to less treatment-related deaths in comparison to conventionally dosed chemotherapy [2, 7] .
Here, we report the 10-year follow-up results for idd versus conventionally dosed chemotherapy.
Patients and methods

Patients
Main inclusion criteria were: women with histologically confirmed primary BC stage II and IIIA with !4positive axillary lymph nodes (ALN); age between 18 and 65 years, M0 status, and R0 resection of the primary tumor and axilla with a minimum of 10 ALN removed. Additional eligibility criteria have been previously published [5] .
The ethics committees of all participating institutions approved the study. All patients provided written informed consent.
Randomization and masking
Randomization was stratified according to institution, number of positive ALN (4-9 versus !10) and menopausal status. Computer-generated randomization lists were used for each stratum and were balanced by block randomization with randomly varying block sizes of 2, 4 and 6. After central review of eligibility, random assignment was done by fax. Patients and treating physicians could not be masked to allocation because of the nature of the interventions, and investigators were not masked since the outcomes (relapse, death) were objectives.
Treatment
Idd treatment consisted of sequential administration of epirubicin (E) (150 mg/m 2 i.v. as bolus infusion) q2w for three cycles, followed by paclitaxel (P) (225 mg/m 2 i.v.) q2w for three cycles, followed by cyclophosphamide (C) (2500 mg/m 2 i.v.) q2w for three cycles. By definition, the iddEPC regimen was dd and used a higher total dose per cycle. Patients received filgrastim subcutaneously days 3-10 of each cycle. Women in the iddEPC arm were additionally randomized to receive or not epoetin alfa during the entire chemotherapy period. The standard treatment consisted of 4 cycles of EC (90/600 mg/m 2 iv.) q3w followed by 4 cycles of paclitaxel (175 mg/m 2 ) q3w (EC!P), without primary growth factor support ( Figure 1 ). Post-study treatment recommendations were extensively published [5] .
Statistical aspects
The primary end point was event-free survival (EFS) defined as locoregional or distant relapse, contralateral invasive BC, second primary cancer occurrence or death for any reason. Secondary end points included overall survival (OS), toxicity and quality of life (QoL).
Totally, 1154 assessable patients had to be recruited and followed for a median period of 5 years in order to achieve 80% power to identify an improvement from 60% to 67% in EFS after 5 years with 5% type I error (one-sided). Some over-recruitment was allowed to increase the statistical validity of the prospectively planned subgroup comparisons in the strata with 4-9 and !10 positive ALN (558 and 598 patients were required to have 80% power for an anticipated improvement from 60% to 70% and 45% to 55%, respectively).
Time to event distributions were estimated using the Kaplan-Meier method [8] , and compared between treatment and prognostic groups using the log-rank test [9] . For multivariable analysis, a Cox proportional hazard model was applied. Either Fisher's exact test or an exact version of the Cochran-Armitage trend test was used to compare toxicity scores. All tests except for the primary hypothesis were two-sided and of explorative nature. This includes all subgroup analyses and multivariable models.
Results
Patient characteristics
A total of 1284 patients were recruited between November 1998 and April 2003 in 165 centers in Germany (iddEPC N ¼ 658, EC ! P N ¼ 626). Six hundred forty-one (97%) and 611 (98%) patients were assessable for the primary end point (supplemen tary Figure S1 , available at Annals of Oncology online). Three patients in the iddEPC arm were considered non-eligible (cardiac arrhythmia, liver metastasis present before randomization, severe wound healing complication). All three patients were excluded from the analysis of the primary end point.
The treatment arms were well balanced with respect to demographic and prognostic factors (Table 1 ). In both study arms, the median number of positive ALN was eight and 42% of the patients had !10 involved ALN.
Treatment
All planned cycles of chemotherapy were administered to 91% of patients in the conventional arm, and to 84% in the idd arm. The predominant causes for treatment discontinuation in the iddEPC arm were toxicity (65% of withdrawals) and patients' preference (20%). Differences in dose reduction and treatment delays have been reported [5] . Relapse during treatment occurred more frequently under conventional dosing (11 versus 3 patients).
Hematological toxicity
Hematological toxicity was more pronounced in the idd arm and the incidence was highest during treatment with cyclophosphamide and modest under paclitaxel. The difference between arms was significant (P < 0.0001) with respect to all three peripheral blood cell lines. Overall, at least one episode of febrile neutropenia was recorded in 5% of the patients (iddEPC arm 7% versus EC ! P 2%, P < 0.0001). Only 6 patients (1%) in the EC ! P arm compared with 127 patients (20%) in the iddEPC arm received red blood cell transfusions (P < 0.0001, Fisher's exact test). The sub-randomization plus/minus Epoetin-alpha had no effect on EFS or OS in the iddEPC arm [10] . Detailed results will be published separately. No treatment-related deaths were observed. Figure 1 . Trial design.
Non-hematological toxicity
Non-hematological toxicity occurred significantly more often in the iddEPC arm, but the overall incidence of grade 3/4 toxicities was low and clinically acceptable ( Table 2) . After 10 years of follow-up, no grade 3 congestive heart failure was observed. One patient died due to cardiac failure after surgery for aortic aneurysm. After a median follow-up of 10 years, 0.7% of the patients in the idd arm compared with 0.2% in the conventionally scheduled group reported persisting grade 1 neuropathy. No persisting grade 2/3 neurotoxicity was observed.
Secondary neoplasms have been observed in 46 patients (iddEPC N ¼ 27, EC ! P N ¼ 19). Acute myeloid leukemia or myelodysplastic syndrome (MDS) were reported in 11 patients during 10-year follow-up (0.9%) (iddEPC N ¼ 9, EC ! P N ¼ 2; P ¼ 0.065).
Efficacy of chemotherapy
After a median follow-up period of 10 years (range 0.1-158 months), 604 events and 446 deaths have been recorded. EFS (282 versus 322 events) and OS (201 versus 245 events) both significantly favored the iddEPC arm. At 10 years, EFS rates for the iddEPC versus EC ! P were 56% (95% CI 52% to 60%) versus 47% (95% CI 43% to 52%), respectively [HR ¼ 0.74, 95% CI (0.63-0.87); log rank test P ¼ 0.00014)], after adjusting for major prognostic baseline parameters in a multivariable model (Figure 2A) . Ten-year survival rates were 69% (95% CI 65% to 73%) in the iddEPC compared with 59% (95% CI 55% to 63%) in the EC ! P arm [HR ¼ 0.72 (95% CI 0.60-0.87); log rank test: P ¼ 0.0007] ( Figure 2B ). In patients with >10 positive ALN OS rates were 62% versus 48% (HR ¼ 0.66; P ¼ 0.0016), whereas in patients with four to nine positive ALN OS rates were 74% versus 66% (HR ¼ 0.77; P ¼ 0.061), respectively.
Prognostic and predictive factors. The results of univariate analyses are listed in Table 3 . At univariate analyses treatment arm, tumor stage, number of positive ALN, tumor grade and hormone receptor status were prognostically relevant for EFS. All parameters identified by univariate analyses retained independent prognostic relevance in a multivariable Cox model.
The impact of treatment arm on EFS in the major subgroups is shown in Figure 3 . Chemotherapy intensification had a more pronounced effect in the subgroup with !10 infiltrated ALN (P ¼ 0.00039). A trend toward greater efficacy for iddEPC in patients with less favorable tumor biology was also observed. Benefit from iddEPC was independent of HER2 and estrogen receptor (ER) expression.
Discussion
Dose-dense adjuvant chemotherapy has become one of the standard treatment options for high-risk BC patients [11] . Several studies with different designs have independently shown that dd chemotherapy results in a superior EFS [2] [3] [4] [5] [6] and OS [2] [3] [4] [5] in comparison to conventionally dosed chemotherapy. Metaanalyses [12, 13] also persistently confirm the superiority of dd chemotherapy in comparison with standard chemotherapy. Long-term follow-up data are necessary to robustly validate the clinical relevance of dd/dose intensified chemotherapy and to help establish their role for the treatment of patients with intermediate/high risk primary BC as a standard of care. Here, we provide the first long-term clinical outcome data of an intense dd chemotherapy regimen.
At 10 years follow-up, EFS and OS continue to be significantly superior for the idd approach, with an absolute difference in OS of 10%. As the 5-year OS data demonstrated an absolute survival difference of 5% (82% versus 77%) in favor of iddEPC [5] , the survival difference has actually increased with longer clinical follow-up. Given the fact that 42% of our patients had !10 positive ALN (median 8 positive ALN), a 10-year survival rate of 69% in the iddEPC arm, represents, to the best of our knowledge, the Cochran-Armitage test: P < 0.0001. n.e., not evaluable. highest survival rate that has been reported for such a high-risk group of patients to date. Importantly, this survival rate was achieved without upfront therapy with aromatase inhibitors, bisphosphonates or trastuzumab. Moreover, the superiority of the iddEPC regimen was independent of menopausal, estrogen receptor and HER2 status. However, not all dd trials have reported improved outcomes. Especially differences in the number of involved nodes (4, 5, 7, 15) and apparent differences in terms of number, total applied dose and schedule of chemotherapy (2, 4, 7, 14, 15) may explain these inconsistent results.
Superiority of dd/idd chemotherapy regimens has only been observed in studies that have accrued high-risk primary BC patients. The CALGB C9741 [2] , GIM-2 [4] and AGO-EPC [5] were positive trials which recruited patients with a median number of three, five and up to eight positive ALN, respectively. In contrast, the UK TACT2 trial [15] and the NSABP B-38 [7] accrued patients with a median number of one or two positive nodes and failed to demonstrate superiority of dd chemotherapy. Eighty-seven % of patients in the UK TACT2 trial were N0 or N1, none of these lower risk patients have been recruited in the AGOiddEPC trial.
Independently of the low-risk profile we cannot exclude that the TAC regimen used in the NSABP B-38 trial may be more effective in comparison to the AC/EC followed by paclitaxel regimen used in the CALGB C9741, GIM-2 and AGO-EPC trials. When these trials were recruiting patients, four cycles of AC or EC followed by four cycles of paclitaxel were a modern standard of care in lymph node positive disease. The recently published 10-year follow-up of the E1199 trial showed superiority between P1 versus P3 only for the triple negative subgroup, but no longer for the largest subgroup of ERþ/HER2À patients [18] . The difference in efficacy may be overestimated for this subgroup.
Other differences in the trial design may help to explain some of the contradictory findings. For example, the GONO-MIG trial [14] used a lower than usually recommended dose of epirubicin in both arms corresponding to only 50% of the dose used in the standard Canadian CEF regimen [16] . The 'dd' arms of the UK TACT2 trial [15] and the Canadian MA21 [17] trial were a 50% split of dd and standard dosed chemotherapy, thus hindering an explicit interpretation of their negative results.
In this context it is also interesting to note that in retrospective subset analyses only the Italian GIM-2 [4] , the tailored dd Panther [6] and the German AGO-EPC [5] trial, but not the CALGB C9741 trial demonstrated superiority of dd chemotherapy also in the subset of ER-positive patients. Especially in the AGO-EPC trial the high risk situation of the patients may effectively override the interaction between dose density and HER2 and/or ER status.
Nine cases (1.4%) of secondary leukemia/MDS were reported in the iddEPC arm versus two cases (0.3%) in the conventional arm. The percentage of 1.4% in the iddEPC arm is consistent with the published data of the 10-year follow-up analysis of the Canadian MA5 trial [16] . Praga et al. [19] reviewed 19 adjuvant trials with epirubicin and cyclophosphamide and patients had an 8-year cumulative probability of secondary leukemia/MDS ranging between 0.37% and 4.97%.
In summary, the iddEPC regimen leads to a relative risk reduction for relapse and death of 26% and 28%, respectively. The iddEPC regimen encompasses the concepts of dose density, dose escalation and sequential therapy. This schedule may increase efficacy both when tumor growth follows Gompertzian kinetics requiring higher density and when partially resistant clones are present requiring higher doses. It is the first trial, which reports 10-year survival and toxicity data for a dd chemotherapy regimen. The absolute survival benefit of 10% appears to be quite remarkable. idd chemotherapy with epirubicin, paclitaxel and cyclophosphamide is an effective and safe regimen. Consistent with other reports on dd trials [2, 4, 6] we also observed no treatment-related death despite a significantly higher hematologic toxicity in the dd arms, Independently of known molecular BC subtypes, dd chemotherapy remains an important treatment option for high-risk BC patients. Future research will need to focus on identifying biomarkers that predict treatment response and will need to evaluate combination therapies with novel targeted agents to further improve treatment outcomes for patients diagnosed with high-risk primary BC.
